Atrium Therapeutics Statistics
Total Valuation
RNA has a market cap or net worth of $217.24 million. The enterprise value is -$47.07 million.
| Market Cap | 217.24M |
| Enterprise Value | -47.07M |
Important Dates
The next estimated earnings date is Friday, June 26, 2026, after market close.
| Earnings Date | Jun 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
RNA has 17.11 million shares outstanding.
| Current Share Class | 17.11M |
| Shares Outstanding | 17.11M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +10.25% |
| Owned by Insiders (%) | 2.80% |
| Owned by Institutions (%) | 82.00% |
| Float | 15.76M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.95 |
| Forward PS | 72.70 |
| PB Ratio | 0.93 |
| P/TBV Ratio | 0.93 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.04, with a Debt / Equity ratio of 0.01.
| Current Ratio | 13.04 |
| Quick Ratio | 12.91 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -21.98% |
| Weighted Average Cost of Capital (WACC) | 9.25% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -142,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | 0.93 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 13.07 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 51.95 |
| Average Volume (20 Days) | 206,319 |
Short Selling Information
The latest short interest is 3.65 million, so 6.62% of the outstanding shares have been sold short.
| Short Interest | 3.65M |
| Short Previous Month | 3.73M |
| Short % of Shares Out | 6.62% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 17.66 |
Income Statement
In the last 12 months, RNA had revenue of $36.68 million and -$58.69 million in losses. Loss per share was -$3.43.
| Revenue | 36.68M |
| Gross Profit | -12.07M |
| Operating Income | -59.46M |
| Pretax Income | -58.83M |
| Net Income | -58.69M |
| EBITDA | -59.04M |
| EBIT | -59.46M |
| Loss Per Share | -$3.43 |
Balance Sheet
The company has $267.85 million in cash and $2.68 million in debt, with a net cash position of $265.17 million or $15.50 per share.
| Cash & Cash Equivalents | 267.85M |
| Total Debt | 2.68M |
| Net Cash | 265.17M |
| Net Cash Per Share | $15.50 |
| Equity (Book Value) | 234.10M |
| Book Value Per Share | 13.69 |
| Working Capital | 263.66M |
Cash Flow
In the last 12 months, operating cash flow was -$61.17 million and capital expenditures -$3.54 million, giving a free cash flow of -$64.71 million.
| Operating Cash Flow | -61.17M |
| Capital Expenditures | -3.54M |
| Depreciation & Amortization | 421,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -64.71M |
| FCF Per Share | -$3.78 |
Margins
Gross margin is -32.91%, with operating and profit margins of -162.10% and -159.99%.
| Gross Margin | -32.91% |
| Operating Margin | -162.10% |
| Pretax Margin | -160.38% |
| Profit Margin | -159.99% |
| EBITDA Margin | -160.95% |
| EBIT Margin | -162.10% |
| FCF Margin | n/a |
Dividends & Yields
RNA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -26.91% |
| FCF Yield | -29.67% |
Analyst Forecast
The average price target for RNA is $25.00, which is 96.85% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $25.00 |
| Price Target Difference | 96.85% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RNA has an Altman Z-Score of 2.84 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.84 |
| Piotroski F-Score | 1 |